Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Traitement de la maladie pulmonaire obstructive chronique (MPOC) avec dysfonctionnement de la diffusion pulmonaire par REGEND001

23 septembre 2026 mis à jour par: Regend Therapeutics

Une recherche multicentrique, randomisée, en simple aveugle, contrôlée par placebo et parallèle sur le produit de thérapie autologue REGEND001 pour le traitement de la maladie pulmonaire obstructive chronique (MPOC) avec dysfonctionnement de la diffusion pulmonaire

Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide with the characterization of obstructed airflow. In a large number of patients, diffusion function is impaired along with the progression of disease. REGEND001 cell therapy, comprised of airway basal cells with ability to regenerate lung tissue, is promising to COPD treatment. In this study, a multicenter, randomized, single-blind, placebo-parallel-controlled trial is performed to assess the efficacy and safety of REGEND001 cell therapy in treatment of chronic obstructive pulmonary disease with diffusion capacity defect.

Aperçu de l'étude

Type d'étude

Interventionnel

Inscription (Réel)

58

Phase

  • Phase 2

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • Beijing Municipality
      • Beijing, Beijing Municipality, Chine
        • China-Japan Friendship Hospital
    • Chongqing Municipality
      • Chongqing, Chongqing Municipality, Chine
        • The Southwest Hospital of AMU
    • Guangdong
      • Guangzhou, Guangdong, Chine
        • The First Affiliated Hospital of Guangzhou Medical University
    • Hunan
      • Changsha, Hunan, Chine, 410008
        • Xiangya Hospital of Central South University
    • Jiangsu
      • Suzhou, Jiangsu, Chine, 215006
        • The First Affiliated Hospital of Soochow University
    • Jiangxi
      • Nanchang, Jiangxi, Chine, 330006
        • The First Affiliated Hospital of Nanchang University
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Chine
        • Shanghai East Hospital
      • Shanghai, Shanghai Municipality, Chine
        • Zhongshan Hospital affiliated to Fudan University

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

40 ans à 75 ans (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Male or female, aged 40 to 75 at the time of signing informed consent.
  • Diagnosed with COPD according to the 2021 Global Initiative for Chronic Obstructive Lung Disease (GOLD).
  • The ratio of forced expiratory volume in one second (FEV1)/forced vital capacity (FVC)FEV1/FVC is < 70% after inhalation of bronchodilators.
  • The diffusion function of carbon monoxide (DLCO) is ≥ 20% and < 80% of the predicted value at screening.
  • Tolerated to pulmonary function tests.
  • Tolerated to bronchoscopy
  • Voluntary to sign the informed consent, coordinated to finish the trial-related procedures and tests, and capable of recording or stating the change of disease condition in a relatively complete manner.

Exclusion Criteria:

  • Females who are pregnant, nursing, or planning to be pregnant within a year after using this product (or males whose spouse planning to be pregnant);

  • Subjects with a positive result for any of the following tests at screening: treponema pallidum antibody (TP-Ab), human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV) antibody. But except the followings:

    1. Hepatitis B virus carriers (only HBsAg positive without any hepatitis symptom or sign, and all liver function tests present normal results or abnormal markers without clinical significance by the assessment of investigators);
    2. Cured hepatitis C patients (negative in HCV ribonucleic acid (RNA) test);
  • Subject with assessed survival time of < 1 year by investigators at screening;

  • Subject with malignant tumors or a history of malignant tumors at screening;

  • Subject with infections in lung or other sites, requiring intravenous drug treatment within a week prior to screening;

  • Subject with more than 4 moderate-to-severe AECOPD, resulting in hospitalization within a year prior to screening;

  • Subject with one or more pathogenetic or serologic findings of the novel coronavirus infection, or symptoms of suspected infection within 6 weeks prior to screening;

  • Subject with a history of invasive or noninvasive mechanical ventilation within 4 weeks prior to screening;

  • Subject who has taken prednisone tablets orally at a dose of ≥ 20 mg/day (or equivalent amount of other oral corticosteroids) within 4 weeks prior to screening;

  • Subject with major lung diseases other than COPD by assessment of investigators at screening;

  • Subject with severe systemic diseases other than lung within 6 months prior to screening and assessed to be inappropriate to participate in this trial by investigators;

  • Subject with severe anemia or poorly controlled granulocyte deficiency, thrombocytopenia by assessment of investigators;

  • Subject with abnormal coagulation and assessed to be negative for the safety of fiberoptic bronchoscopy operations at screening;

  • Subject requiring long-term anticoagulation therapy of using antiplatelet coagulant therapeutic agents and disable to discontinue their medications 1 week prior to cell collection and cell infusion as assessed by investigators;

  • Subject with a risk of suicide, a history of mental illness or a history of epilepsy at screening;

  • Subject with severe arrhythmias or heart conduction disorders (degree II or above) in 12-lead ECG test at screening;

  • Subject participated in other clinical trials with interventions within 3 months prior to screening;

  • Investigators, co-investigators, research coordinators, employees of research participants or research centers, or their family members;

  • Any circumstance considered to probably increase the risk of patients or interfere with the clinical trial.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Seul

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Comparateur placebo: Placebo

Placebo

Transplantation of Placebo

Expérimental: REGEND001 cell therapy

REGEND001 cell therapy

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Responsive rate (RR)
Délai: 12 weeks after treatment, 24 weeks after treatment

Ratio of subjects responsive to the treatment. Subject is considered to be responsive to the treatment as (1) the lung diffusing capacity for carbon monoxide (DLCO) improvement meets MCID (minimal clinically important difference) at 12 or/and 24 weeks after therapy; and (2) mean of DLCO at 12 and 24 weeks is no less than the baseline value. MCID of DLCO improvement is 1.1 ml/min/mmHg (0.37 mmol·min -1·kPa-1) or 11% for measured value compared to baseline .

12 weeks after treatment, 24 weeks after treatment

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Change of lung diffusing capacity for carbon monoxide (DLCO) from baseline
Délai: Within 52 weeks after treatment

DLCO is considered a measure of the conductance of CO across the alveolar-capillary membrane and its binding with hemoglobin.

Within 52 weeks after treatment
Change of the alveolar volume (VA) from baseline
Délai: Winthin 52 weeks after treatment

Alveolar ventilation is the exchange of gas between the alveoli and the external environment. It is the process by which oxygen is brought into the lungs from the atmosphere and by which the carbon dioxide carried into the lungs in the mixed venous blood is expelled from the body.

Winthin 52 weeks after treatment
Change of images of lung by high resolution computed tomography (HR-CT) from baseline
Délai: Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment

HR-CT images of lung will be analyzed to indicate the change of pulmonary structure.

Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
Change of forced vital capacity (FVC) from baseline
Délai: Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment

FVC is the full amount of air that can be exhaled with effort in a complete breath.

Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
Change of forced expiratory volume in one second (FEV1) from baseline
Délai: Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment

FEV1 is the volume of breath exhaled with effort in one second.

Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
Change of forced expiratory volume in one second (FEV1)/forced vital capacity (FVC) from baseline
Délai: Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment

The FEV1/FVC is a ratio that reflects the amount of air you can forcefully exhale from your lungs. It's measured by spirometry, a test used to evaluate lung function.

Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
Change of the diffusing capacity for carbon monoxide/ the alveolar volume (DLCO/VA) from baseline
Délai: Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment

The DLCO test refers to the diffusing capacity for carbon monoxide in the lungs. It's a type of pulmonary function test that helps to assess how well gas is exchanged between the lungs and the bloodstream.Since DLCO is affected by the amount of inhaled gas and lung volume, the subject's alveolar ventilation (VA) is also considered when evaluating diffusion function to exclude the effect of lung volume on diffusion volume.

Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
Change of 6-minute-walk test (6MWT) from baseline
Délai: Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment

The 6MWT is a commonly used test for the objective assessment of functional exercise capacity by testing the distance patients can walk at the fastest speed within 6 minutes.

Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
Change of modified medical research council (mMRC) dyspnea scale from baseline
Délai: Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment

It is a questionnaire to evaluate how breathlessness impacts daily activities. According to the degree of activity impacted by shortness of breath, mMRC results are divided into 0-4 grades. Grade 0 means no breathlessness except on strenuous exercise; grade 1 means shortness of breath when hurrying on the level or walking up a slight hill; grade 2 means walking slower than people of same age on the level because of breathlessness or having to stop to catch breath when walking at their own pace on the level; grade 3 means stoping for breath after walking ∼100 m or after few minutes on the level ground; and grade 4 means too breathless to leave the house, or breathless when dressing or undressing.

Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
Change of chronic obstructive pulmonary disease Assessment Test (CAT) from baseline
Délai: Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment

The CAT is a questionnaire for people with COPD. It is designed to measure the impact of COPD on a person's life, and how this changes over time. The CAT scale includes a total of 8 items, 0~5 points for each item. The total score ranges 0~40 points. Score of 0-10 points indicates slight impact; Score of 11-20 points indicates medium impact: Score of 21-30 points indicates serious impact; Score of 31-40 points indicates very serious impact.

Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
Annual frequency of exacerbations
Délai: 1 year after treatment

Frequency of exacerbations all through the year. A lower frequency means improvement of disease.

1 year after treatment
Symptoms, physical examination
Délai: Baseline, treatment day (D1), 24 hours after treatment, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment

Number of cases with abnormal physical examination findings.

Baseline, treatment day (D1), 24 hours after treatment, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
12-lead ECG
Délai: 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment

Number of cases with abnormal 12-lead Electrocardiogram (ECG).

4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
Blood routine
Délai: Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment

Number of cases with abnormal laboratory test results.

Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
Urine routine
Délai: Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment

Number of cases with abnormal laboratory test results.

Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
Blood biochemistry
Délai: Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment

Number of cases with abnormal laboratory test results.

Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
Function of blood clotting
Délai: Baseline, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment

Number of cases with abnormal function of blood clotting.

Baseline, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
Carcinoembryonic antigen (CEA)
Délai: Baseline, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment

CEA is a tumor marker used for early diagnosis of lung cancer.

Baseline, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
Neuron-specific enolase (NSE)
Délai: Baseline, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment

NSE is a tumor marker significantly elevated in small cell lung cancer.

Baseline, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
Cytokeratin-19-fragment (CYFRA21-1)
Délai: Baseline, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment

CYFRA21-1 is a tumor marker which is valuable for the pathological classification and prognosis evaluation of lung cancer.

Baseline, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
Squamous cell carcinoma antigen (SCC)
Délai: Baseline, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment

SCC is a specific marker for lung squamous cell carcinoma.Tumor markers are monitored to assess the safety.

Baseline, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

6 décembre 2022

Achèvement primaire (Réel)

9 juillet 2025

Achèvement de l'étude (Réel)

9 juillet 2025

Dates d'inscription aux études

Première soumission

2 novembre 2022

Première soumission répondant aux critères de contrôle qualité

25 novembre 2022

Première publication (Réel)

6 décembre 2022

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

28 septembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

23 septembre 2026

Dernière vérification

1 juillet 2025

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner